| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = -$602,351 ) |
| | 2024 | 2022 | XEQUEL BIO, INC. | 777 TAYLOR ST STE 1140 | FORT WORTH | TX | 76102-4921 | TARRANT | USA | R44DK125244 | Improving marginal allograft outcomes through cell junction stabilization in transplantation | 001 | 3 | NIH | 7/15/2024 | -$392,199 |
| | 2024 | 2022 | XEQUEL BIO, INC. | 777 TAYLOR ST STE 1140 | FORT WORTH | TX | 76102-4921 | TARRANT | USA | R43EY033605 | Evaluation of a Connexin-based Peptide for the Treatment of Diabetic Retinopathy | 002 | 1 | NIH | 9/19/2024 | -$210,151 |
| | 2024 | 2022 | XEQUEL BIO, INC. | 1501 BELLE ISLE AVE STE 220 | MOUNT PLEASANT | SC | 29464-8380 | CHARLESTON | USA | R43EY033605 | Evaluation of a Connexin-based Peptide for the Treatment of Diabetic Retinopathy | 001 | 1 | NIH | 3/22/2024 | $0 |
| | 2024 | 2022 | XEQUEL BIO, INC. | 1501 BELLE ISLE AVE STE 220 | MOUNT PLEASANT | SC | 29464-8380 | CHARLESTON | USA | R44DK125244 | Improving marginal allograft outcomes through cell junction stabilization in transplantation | 000 | 3 | NIH | 4/10/2024 | $0 |
| | 2024 | 2022 | XEQUEL BIO, INC. | 1501 BELLE ISLE AVE STE 220 | MOUNT PLEASANT | SC | 29464-8380 | CHARLESTON | USA | R43EY033605 | Evaluation of a Connexin-based Peptide for the Treatment of Diabetic Retinopathy | 000 | 1 | NIH | 10/16/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2020 | XEQUEL BIO, INC. | 1501 BELLE ISLE AVE STE 220 | MOUNT PLEASANT | SC | 29464-8380 | CHARLESTON | USA | R43HL154975 | Evaluation of a Novel Therapeutic Approach to Treat Alcoholic Lung Syndrome | 000 | 1 | NIH | 5/15/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $1,254,115 ) |
| | 2022 | 2022 | XEQUEL BIO, INC. | 1501 BELLE ISLE AVE STE 220 | MOUNT PLEASANT | SC | 29464-8380 | CHARLESTON | USA | R43EY033605 | Evaluation of a Connexin-based Peptide for the Treatment of Diabetic Retinopathy | 000 | 1 | NIH | 9/8/2022 | $314,875 |
| | 2022 | 2022 | XEQUEL BIO, INC. | 1501 BELLE ISLE AVE STE 220 | MOUNT PLEASANT | SC | 29464-8380 | CHARLESTON | USA | R44DK125244 | Improving marginal allograft outcomes through cell junction stabilization in transplantation | 006 | 3 | NIH | 9/7/2022 | $987,481 |
| | 2022 | 2021 | XEQUEL BIO, INC. | 1501 BELLE ISLE AVE STE 220 | MOUNT PLEASANT | SC | 29464-8380 | CHARLESTON | USA | R44DK125244 | Improving marginal allograft outcomes through cell junction stabilization in transplantation | 002 | 2 | NIH | 3/22/2022 | $225,000 |
| | 2022 | 2021 | FIRSTSTRING RESEARCH, INC | 300 WEST COLEMAN BOULEVARD SUITE 203 | MOUNT PLEASANT | SC | 29464-5641 | CHARLESTON | USA | R44DK125244 | Improving marginal allograft outcomes through cell junction stabilization in transplantation | 000 | 2 | NIH | 12/8/2021 | $0 |
| | 2022 | 2021 | XEQUEL BIO, INC. | 1501 BELLE ISLE AVE STE 220 | MOUNT PLEASANT | SC | 29464-8380 | CHARLESTON | USA | R44DK125244 | Improving marginal allograft outcomes through cell junction stabilization in transplantation | 004 | 2 | NIH | 3/23/2022 | -$225,000 |
| | 2022 | 2020 | XEQUEL BIO, INC. | 1501 BELLE ISLE AVE STE 220 | MOUNT PLEASANT | SC | 29464-8380 | CHARLESTON | USA | R44DK125244 | Improving marginal allograft outcomes through cell junction stabilization in transplantation | 005 | 1 | NIH | 6/10/2022 | $0 |
| | 2022 | 2020 | XEQUEL BIO, INC. | 1501 BELLE ISLE AVE STE 220 | MOUNT PLEASANT | SC | 29464-8380 | CHARLESTON | USA | R44CA195937 | Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide | 000 | 3 | NIH | 2/4/2022 | -$48,241 |
| | 2022 | 2020 | FIRSTSTRING RESEARCH, INC | 300 WEST COLEMAN BOULEVARD SUITE 203 | MOUNT PLEASANT | SC | 29464-5641 | CHARLESTON | USA | R43HL154975 | Evaluation of a Novel Therapeutic Approach to Treat Alcoholic Lung Syndrome | 002 | 1 | NIH | 3/22/2022 | $0 |
| | 2022 | 2020 | FIRSTSTRING RESEARCH, INC | 300 WEST COLEMAN BOULEVARD SUITE 203 | MOUNT PLEASANT | SC | 29464-5641 | CHARLESTON | USA | R43HL154975 | Evaluation of a Novel Therapeutic Approach to Treat Alcoholic Lung Syndrome | 001 | 1 | NIH | 2/7/2022 | $0 |
| | 2022 | 2020 | XEQUEL BIO, INC. | 1501 BELLE ISLE AVE STE 220 | MOUNT PLEASANT | SC | 29464-8380 | CHARLESTON | USA | R43HL154975 | Evaluation of a Novel Therapeutic Approach to Treat Alcoholic Lung Syndrome | 000 | 1 | NIH | 2/2/2022 | $0 |
| | 2022 | 2020 | XEQUEL BIO, INC. | 1501 BELLE ISLE AVE STE 220 | MOUNT PLEASANT | SC | 29464-8380 | CHARLESTON | USA | R44DK125244 | Improving marginal allograft outcomes through cell junction stabilization in transplantation | 001 | 1 | NIH | 3/22/2022 | -$225,000 |
| | 2022 | 2020 | XEQUEL BIO, INC. | 1501 BELLE ISLE AVE STE 220 | MOUNT PLEASANT | SC | 29464-8380 | CHARLESTON | USA | R44DK125244 | Improving marginal allograft outcomes through cell junction stabilization in transplantation | 003 | 1 | NIH | 3/23/2022 | $225,000 |
|
| Issue Date FY: 2021 ( Subtotal = $993,803 ) |
| | 2021 | 2021 | FIRSTSTRING RESEARCH, INC | 300 WEST COLEMAN BOULEVARD SUITE 203 | MOUNT PLEASANT | SC | 29464-5641 | CHARLESTON | USA | R44DK125244 | Improving marginal allograft outcomes through cell junction stabilization in transplantation | 000 | 2 | NIH | 6/23/2021 | $993,803 |
| | 2021 | 2020 | FIRSTSTRING RESEARCH, INC | 300 WEST COLEMAN BOULEVARD SUITE 203 | MOUNT PLEASANT | SC | 29464-5641 | CHARLESTON | USA | R43HL154975 | Evaluation of a Novel Therapeutic Approach to Treat Alcoholic Lung Syndrome | 000 | 1 | NIH | 11/24/2020 | $0 |
| | 2021 | 2019 | FIRSTSTRING RESEARCH, INC | 300 WEST COLEMAN BOULEVARD SUITE 203 | MOUNT PLEASANT | SC | 29464-5641 | CHARLESTON | USA | R43AI142887 | Evaluation of a Novel Connexin-Based Peptide in the Treatment of Combined Ionizing Radiation and Thermal Burn Injury | 000 | 1 | NIH | 9/10/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $652,131 ) |
| | 2020 | 2020 | FIRSTSTRING RESEARCH, INC | 300 WEST COLEMAN BOULEVARD SUITE 203 | MOUNT PLEASANT | SC | 29464-5641 | CHARLESTON | USA | R43HL154975 | Evaluation of a Novel Therapeutic Approach to Treat Alcoholic Lung Syndrome | 000 | 1 | NIH | 8/21/2020 | $252,131 |
| | 2020 | 2020 | FIRSTSTRING RESEARCH, INC | 300 WEST COLEMAN BOULEVARD SUITE 203 | MOUNT PLEASANT | SC | 29464-5641 | CHARLESTON | USA | R44CA195937 | Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide | 002 | 3 | NIH | 9/14/2020 | $100,000 |
| | 2020 | 2020 | FIRSTSTRING RESEARCH, INC | 300 WEST COLEMAN BOULEVARD SUITE 203 | MOUNT PLEASANT | SC | 29464-5641 | CHARLESTON | USA | R44DK125244 | Improving marginal allograft outcomes through cell junction stabilization in transplantation | 000 | 1 | NIH | 4/15/2020 | $300,000 |
| | 2020 | 2019 | FIRSTSTRING RESEARCH, INC | 300 WEST COLEMAN BOULEVARD SUITE 203 | MOUNT PLEASANT | SC | 29464-5641 | CHARLESTON | USA | R43AI142887 | Evaluation of a Novel Connexin-Based Peptide in the Treatment of Combined Ionizing Radiation and Thermal Burn Injury | 000 | 1 | NIH | 11/6/2019 | $0 |
| | 2020 | 2019 | FIRSTSTRING RESEARCH, INC | 300 WEST COLEMAN BOULEVARD SUITE 203 | MOUNT PLEASANT | SC | 29464-5641 | CHARLESTON | USA | R44CA195937 | Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide | 000 | 3 | NIH | 12/20/2019 | $0 |
| | 2020 | 2018 | FIRSTSTRING RESEARCH, INC | 300 WEST COLEMAN BOULEVARD SUITE 203 | MOUNT PLEASANT | SC | 29464-5641 | CHARLESTON | USA | R44CA195937 | Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide | 001 | 2 | NIH | 12/23/2019 | $0 |
| | 2020 | 2017 | FIRSTSTRING RESEARCH, INC | 300 WEST COLEMAN BOULEVARD SUITE 203 | MOUNT PLEASANT | SC | 29464-5641 | CHARLESTON | USA | R41AR070681 | A Novel Scaffold to Promote Skin Regeneration | 000 | 1 | NIH | 1/14/2020 | $0 |
| | 2020 | 2017 | FIRSTSTRING RESEARCH, INC | 300 WEST COLEMAN BOULEVARD SUITE 203 | MOUNT PLEASANT | SC | 29464-5641 | CHARLESTON | USA | R43EY028072 | Evaluation of a Connexin-based Peptide for the Treatment of Age-Related Macular Degeneration | 000 | 1 | NIH | 9/4/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $955,532 ) |
| | 2019 | 2019 | FIRSTSTRING RESEARCH, INC | 300 WEST COLEMAN BOULEVARD SUITE 203 | MOUNT PLEASANT | SC | 29464-5641 | CHARLESTON | USA | R43AI142887 | Evaluation of a Novel Connexin-Based Peptide in the Treatment of Combined Ionizing Radiation and Thermal Burn Injury | 000 | 1 | NIH | 4/15/2019 | $300,000 |
| | 2019 | 2019 | FIRSTSTRING RESEARCH, INC | 300 WEST COLEMAN BOULEVARD SUITE 203 | MOUNT PLEASANT | SC | 29464-5641 | CHARLESTON | USA | R44CA195937 | Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide | 000 | 3 | NIH | 8/28/2019 | $655,532 |
| | 2019 | 2018 | FIRSTSTRING RESEARCH, INC | 300 WEST COLEMAN BOULEVARD SUITE 203 | MOUNT PLEASANT | SC | 29464-5641 | CHARLESTON | USA | SB1DK080567 | Evaluation of a Novel Connexin-Based Peptide for the Treatment of Diabetic Wounds | 000 | 8 | NIH | 3/1/2019 | $0 |
| | 2019 | 2017 | FIRSTSTRING RESEARCH, INC | 300 WEST COLEMAN BOULEVARD SUITE 203 | MOUNT PLEASANT | SC | 29464-5641 | CHARLESTON | USA | R43EY028072 | Evaluation of a Connexin-based Peptide for the Treatment of Age-Related Macular Degeneration | 000 | 1 | NIH | 3/15/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $988,610 ) |
| | 2018 | 2018 | FIRSTSTRING RESEARCH, INC | 300 WEST COLEMAN BOULEVARD SUITE 203 | MOUNT PLEASANT | SC | 29464-5641 | CHARLESTON | USA | R44CA195937 | Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide | 001 | 2 | NIH | 9/7/2018 | $0 |
| | 2018 | 2018 | FIRSTSTRING RESEARCH, INC | 300 WEST COLEMAN BOULEVARD SUITE 203 | MOUNT PLEASANT | SC | 29464-5641 | CHARLESTON | USA | R44CA195937 | Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide | 000 | 2 | NIH | 9/6/2018 | $841,361 |
| | 2018 | 2018 | FIRSTSTRING RESEARCH, INC | 300 WEST COLEMAN BOULEVARD SUITE 203 | MOUNT PLEASANT | SC | 29464-5641 | CHARLESTON | USA | SB1DK080567 | Evaluation of a Novel Connexin-Based Peptide for the Treatment of Diabetic Wounds | 000 | 8 | NIH | 6/29/2018 | $147,249 |
| | 2018 | 2016 | FIRSTSTRING RESEARCH, INC | 300 WEST COLEMAN BOULEVARD SUITE 203 | MOUNT PLEASANT | SC | 29464-5641 | CHARLESTON | USA | R43HL131360 | Stabilization of gap/tight junctions to ameliorate brain death induced endothelial cell injury | 000 | 1 | NIH | 1/4/2018 | $0 |
| | 2018 | 2015 | FIRSTSTRING RESEARCH, INC | 300 WEST COLEMAN BOULEVARD SUITE 203 | MOUNT PLEASANT | SC | 29464-5641 | CHARLESTON | USA | R43CA195937 | Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide | 000 | 1 | NIH | 10/27/2017 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $1,302,751 ) |
| | 2017 | 2017 | FIRSTSTRING RESEARCH, INC | 300 WEST COLEMAN BOULEVARD SUITE 203 | MOUNT PLEASANT | SC | 29464-5641 | CHARLESTON | USA | R43EY028072 | Evaluation of a Connexin-based Peptide for the Treatment of Age-Related Macular Degeneration | 000 | 1 | NIH | 8/17/2017 | $225,000 |
| | 2017 | 2017 | FIRSTSTRING RESEARCH, INC | 300 WEST COLEMAN BOULEVARD SUITE 203 | MOUNT PLEASANT | SC | 29464-5641 | CHARLESTON | USA | R41AR070681 | A Novel Scaffold to Promote Skin Regeneration | 000 | 1 | NIH | 9/14/2017 | $225,000 |
| | 2017 | 2017 | FIRSTSTRING RESEARCH, INC | 300 WEST COLEMAN BOULEVARD SUITE 203 | MOUNT PLEASANT | SC | 29464-5641 | CHARLESTON | USA | SB1DK080567 | Evaluation of a Novel Connexin-Based Peptide for the Treatment of Diabetic Wounds | 000 | 7 | NIH | 8/8/2017 | $852,751 |
| | 2017 | 2016 | FIRSTSTRING RESEARCH, INC | 300 WEST COLEMAN BOULEVARD SUITE 203 | MOUNT PLEASANT | SC | 29464-5641 | CHARLESTON | USA | R44DK080567 | Evaluation Of A Novel Connexin-Based Peptide For The Treatment Of Diabetic Wounds | 000 | 6 | NIH | 7/21/2017 | $0 |
|
|
